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Abstract 
Background: To compare antimicrobial 
susceptibility pattern of fosfomycin and 
nitrofurantoin against multi-drug resistant gram 
negative uropathogens. 
Methods: In this descriptive study identification of 
200 isolates of gram negative bacteria was done by 
using standard microbiological techniques and the 
antimicrobial susceptibility was carried out by 
employing Kirby-Bauer disc diffusion technique. 
The  susceptibility pattern of isolates was then 
recorded in frequency and percentages. 
Results: Out of total 200 urinary samples, 97 were 
multi-drug resistant (MDR) and 103 were non multi-
drug resistant gram negative bacteria. Both MDR 
and non MDR Escherichia coli(E. coli) followed by 
Klebsiella pneumoniae(K. pneumoniae) were more 
commonly isolated uropathogens. MDR E. coli was 
more susceptible to fosfomycin (98%) as compared to 
nitrofurantoin (81%). Similarly, for MDR K. 
pneumoniae, same results of better susceptibility of 
fosfomycin as compared to nitrofurantoin were 
observed. Maximum resistance was observed in 4 to 
5 drugs in MDR E.coli and K. pneumonia and the 
most predominant resistant pattern was observed in 
ampicillin and cephalosporins . 
Conclusion: Fosfomycin holds much better in vitro 
efficacy as compared to nitrofurantoin against MDR 
E. coli, K. pneumoniae and P. stuartii. 
Key Words:Enterobacteriaceae, Fosfomycin, Multi-
drug resistant, Nitrofurantoin. 
  
Introduction 
Urinary tract infections (UTIs) are among the most 
commonly observed infections in clinical practice.1One 
of the most important challenges is to deal with 
recurrent UTI in women.2,3 But, approximately one 
third or more of hospital-acquired infections are 
preventable.4 The gram negative organisms which 
usually cause UTI include Escherichia coli (E. coli), 
Proteus species, Klebsiella species, Citrobacter species 
and Pseudomonas aeruginosa.5 The development of 
antimicrobial resistance among various Gram-negative 
pathogens has been progressive. Another problem is of 
multi-drug resistance in Enterobacteriaceae causing 
urinary tract infections.6 Multi-drug resistance in gram 
negative isolates is defined as resistance to at least one 
agent in three or more than three antimicrobial 
categories.7 Trimethoprim-sulfamethoxazole and 
ampicillin use in the past have remained choices for 
treating uncomplicated urinary tract infections which 
are now losing their efficacy.8The extended spectrum 
cephalosporins and quinolones which are used as first-
line therapy have also shown emergence of resistance. 
The resistant genes have predominated among 
hospital-acquired organisms. In particular, CTX-M-15 
is the most widespread and this β-lactamase has 
frequently been associated with uropathogenic E. coli 
clone.6 As the agents commonly used to treat these 
pathogens have become outmoded. Of the few new 
drugs available, many have already become 
resistant.9Due to current situation, the use of 
fosfomycin and nitrofurantoin are returning, owing to 
its broad spectrum activity against both gram positive 
and Gram negative bacteria.10,11Fosfomycin is a unique 
antibiotic that is chemically different from any other 
known antibacterial agent.The drug is well tolerated 
and has a low incidence of harmful side-effects.12 It has 
shown better in vitro activity against Extended-
spectrum β-lactamase (ESBL) producing E. coli and 
Klebsiella pneumoniae(K. pneumoniae) with in 
particular good activity against ESBL producing 
urinary Enterobacteriaceae.13However, development 
of bacterial resistance under therapy is a frequent 
occurrence and makes fosfomycin unsuitable for 
prolonged therapy as regards severe infections.14 
Nitrofurantoin is bactericidal and its mechanism of 
action is unique from usual antimicrobials. It stops 
biochemical processes involving DNA and RNA 
synthesis by producing reactive intermediates as a 
result of reduction with bacterial flavoproteins and 
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finally cell wall synthesis also halts.It has particularly 
better activity against MDR urinary pathogens. Rare 
resistant mutants and its uncommon cross resistance 
with other antimicrobials makes worth its use in Gram 
negative urinary tract infections.15,16 The global 
problem of accelerating antimicrobial resistance has 
revived interest in use of fosfomycin and 
nitrofurantoin more recently. 
 
Patients and Methods 
This descriptive study was conducted in department 
of Microbiology, Fauji Foundation Hospital, 
Rawalpindi/Foundation University Medical College, 
Islamabad campus from January 2015 to October 2015. 
Total 200 urinary isolates were considered for study. 
All gram negative bacteria from urinary isolates 
received from Medicine, Surgery, 
Gynaecology/Obstetrics and Paediatric wards (indoor 
and outdoor) of Fauji Foundation Hospital, 
Rawalpindi were included in the study. All duplicate 
samples, patients already receiving antimicrobials for 
UTI or other ailment were excluded from the study. 
All gram negative urinary isolates were collected from 
the patients admitted in different units of Fauji 
Foundation Hospital, Rawalpindi. Urine specimens 
were inoculated on Cysteine Lactose Electrolyte 
Deficient (CLED) agar and incubated aerobically at 35 
± 20C for 16 to 18 hours.  Gram negative rods were 
identified by colony morphology, Gram staining, 
biochemical reactions and confirmed by API 20E. 
Antimicrobial susceptibility testing was performed by 
Kirby Bauer’s disc diffusion method, according to 
guidelines published by the Clinical Laboratory 
Standards Institute (CLSI). All gram negative urinary 
isolates were tested by ampicillin (25 µg), ceftriaxone 
(30 µg), aztreonam (30 µg), gentamicin (10 µg), 
amikacin (30 µg), ciprofloxacin (5 µg), imipenem (10 
µg), nitrofurantoin (300 µg), fosfomycin (200 µg) and 
trimethoprim-sulfamethoxazole (1.25/ 23.75 µg) discs. 
Standard strain of Escherichia coli using American 
Type Culture Collection(ATCC 25922) was included in 
each batch of tests. Incubation was done at 35+ 20C for 
16- 18 hours. All zone sizes were interpreted according 
to CLSI.17 Isolates showing resistance to at least one 
agent in three or more than three antimicrobial 




Out of total 200 urinary isolates, 97 were MDR and 103 
were non-MDR Gram negative bacteria. Highest 
number of bacteria isolated was E. coli followed by K. 
pneumoniae and least isolated pathogen was 
Providencia stuartii (P. stuartii). Only E. coli(n= 89), K. 
pneumoniae(n= 4)and P. stuartii(n= 4) were isolated as 
MDR (Table 1).Overall nitrofurantoin showed 
maximum resistance in MDRP. stuartii(67%), K. 
pneumoniae(60%) and E. coli(19%) as compared to 
fosfomycin (Table 2).Percentage of resistance to three 
drugs was almost the same for MDR E. coli and MDR 
K. pneumoniae. Resistance to four to five drugs was 
maximum in MDR E. coli. Whereas, for six drugs the 
resistance was maximum inMDR K. pneumoniae as 
compared to MDR E. coli (Table3 ). 
Table 1: Distribution of MDR and non 










E. coli 163 74 (37%) 89 44.5%) 
K. pneumoniae 19 15 (7.5%) 4 (2%) 
P. stuartii 6 2 (1%)  4    (2%) 
P. rettgeri 3 3(1.5%) - 
Proteus mirabilis 5 5 (2.5%)  - 
C. freundii 4 4 (2%)  - 
Total 200 100% - 
Table 2: Susceptibility pattern of MDR 
producing Gram negative rods against 





n Fosfomycin Nitrofurantoin 
Susceptible  Resistant Susceptible Resistant 
E. coli 89 87 (98%) 2 (2%) 72(81%) 17 (19%) 
Klebsiella 
pneumonia 
5 3(60%) 2 (40%) 2 (25%) 3 (60%) 
Providencias 
Stuartii 
3 2  (67%) 1 (33%) 1 (33%) 2(67%) 
Table 3.  Multi drug resistance of urinary E. coli 





































AMP- Ampicillin;CRO- Ceftriaxone;GEN- Gentamicin;SXT- 
Trimethoprim-sulfamethoxazole;CIP-Ciprofloxacin;AMK- 
Amikacin;IPM- Imipenem;ATM- Aztreonam 
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Discussion 
Urinary tract infection takes the second lead after 
respiratory tract infection in community acquired 
infections.18One of serious health problem is 
threatening rise in resistance to antimicrobials.19In our 
study, out of 97 MDR gram negative urinary isolates, 
multi-drug resistance in E. coli was predominant 
(44.5%) as compared to K. pneumoniae (2%). A study 
from Iran reported 50% MDR E. coli and 46.6% MDR 
K. pneumoniae which is more than our 
results.20.Another study conducted in USA shows 
almost similar results with high multi-drug resistance 
in E.coli (76%) as compared to K.pneumoniae(5%).21 
Similar group of bacteria reveals multi-drug resistance 
reported in Nepal, E. coli (74%) and K. pneumoniae 
(44%) and Ethiopia,E.coli (94.6%) and K. pneumoniae 
(80%).22,23The higher MDR rates in these previous 
studies may be due to genetic, geographical and social 
variations in different regions. However, unlike our 
study Khawcharoenporn et al isolated 6% of MDR 
Proteus mirabilis and Citrobacter species and only 2% 
of Providencia species.21 
 Better susceptibility results of fosfomycin in present 
study as compared to nitrofurantoin against MDR 
urinary E. coli, Klebsiella and P. stuartii have backed 
up the use of fosfomycin. About 98% of MDR E. coli 
isolates were susceptible to fosfomycin and 81% to 
nitrofurantoin in our study. These results coincided 
with a study conducted in Taiwan against MDR E.coli, 
where 95.5% and 75.1% isolates were susceptible to 
fosfomycin and nitrofurantoin respectively.24 Bano et 
al concluded maximum susceptibility to fosfomycin 
(100%) and nitrofurantoin (100%) against K. 
pneumoniae in a study conducted in Pakistan. 
Whereas, for E. coli, 89.28% and 96.43% of isolates 
were susceptible to fosfomycin and nitrofurantoin 
respectively.25On the contrary, a study conducted in 
Dera Ismael Khan showed fosfomycin susceptibility 
against E.coli (97.2%) was much better than K. 
pneumoniae (3.6%) which was in agreement to the 
findings of this present study.26 Similar results of better 
susceptibility of fosfomycin against MDR E. coli and K. 
pneumoniae were again almost consistent with a study 
conducted by Liu et al.24 The resistant rates of 
fosfomycin and nitrofurantoin against E. coli were 
0.3% and 4% respectively in a study conducted in 
Turkey.27 
In present study, 20% of MDR E.coli isolates showed 
resistance to 3 drugs. Similar studies  from Pakistan 
and Iran also showed 20% of isolates were resistant to 
less than 5 drugs and 3 drugs respectively. 28,29In our 
study, maximum resistance was observed in 4-5 drugs 
(62%) against MDR E. coli with ampicillin-cefriaxone-
trimethoprim-sulfamethoxazole-ciprofloxacin- 
gentamicin being the predominant resistant pattern. A 
study from Iran revealed the trend of maximum 
antimicrobial resistance was more in favor of 3 drugs 
against MDR E. coli namely ampicillin, tetracycline 
and trimethoprim-sulfamethoxazole.29This high 
resistance pattern in our set up may be due to over the 
counter use of antimicrobials. A study from Sudan 
reported MDR E. coli resistance to more than 8 drugs 
with most frequent resistance pattern of ampicillin, 
amoxicillin, tetracycline, trimethoprim-
sulfamethoxazole and sulfonamide.30As regards, MDR 
K. pneumoniae, more resistance was observed in 6 
drugs in which ampicillin and ceftriaxone were 
observed as the most predominant resistant pattern. 
The resistance in other classes was almost equal in 
number. There is not enough data available to support 
the phenotypic resistance pattern of antimicrobials 
against MDR K. pneumoniae. However, a study 
conducted in Morocco, showed maximum resistance in 
MDR K. pneumoniae to amoxicillin-clavulinic acid 
followed by trimethoprim-sulfamethoxazole.31 
Several studies on fosfomycin from different parts of 
the world have shown that resistance to this drug is 
still very low.26It has broad spectrum activity against 
E. coli, Citrobacter spp, Klebsiellaspp, Proteus spp., 
Pseudomonas aeruginosa, Serratia spp and Salmonella 
spp.It has effective tissue penetration and single oral 
dose with less side effects as compared to 
nitrofurantoin.32Asthese findings are in vitro, more 
clinical trials are needed to support both drugs efficacy 
in vivo. Still more research is needed on the use of 
fosfomycin for complicated urinary tract infections 
and non-urinary tract infections which has not been 
extensively evaluated in our setup. 
 
Conclusion 
Fosfomycin reserves its  in vitro activity against MDR 
E. coli, K. Pneumonia and P. Stuartii when compared 
to nitrofurantoin. Fosfomycinhas shown in particular 
potent results against MDR E.coli. Keeping in view, its 
better susceptibility results and convenient use, it can 
be used as an empirical therapy in treating 
uncomplicated UTIs in our setup. 
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